Get started
Award

C12540/A13230

Funded outputs count: 8
Funder award ID: C12540/A13230
OpenAlex ID: G247767775
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
2024 · George Seed, Nick Beije, et al. · Cancer Cell · 51
RNASEH2B loss and PARP inhibition in advanced prostate cancer
2024 · Juliet Carmichael, Ines Figueiredo, et al. · Journal of Clinical Investigation · 10
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
2021 · Suzanne Carreira, Nuria Porta, et al. · Cancer Discovery · 160
PDF
Characterizing CDK12-Mutated Prostate Cancers
2020 · Pasquale Rescigno, Bora Gurel, et al. · Clinical Cancer Research · 99
Genomics of lethal prostate cancer at diagnosis and castration resistance
2019 · Joaquin Mateo, George Seed, et al. · Journal of Clinical Investigation · 314
PDF
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
2019 · Joaquin Mateo, Nuria Porta, et al. · The Lancet Oncology · 634
PDF
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
2017 · Jane Goodall, Joaquin Mateo, et al. · Cancer Discovery · 420
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
2015 · Joaquin Mateo, Suzanne Carreira, et al. · New England Journal of Medicine · 2,185
PDF
Year
Topic